We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
+$35.6M
Cap. Flow
+$28.1M
Cap. Flow %
18.99%
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$4.65M
2
ALGN icon
Align Technology
ALGN
+$4.41M
3
GERN icon
Geron
GERN
+$4.12M
4
GILD icon
Gilead Sciences
GILD
+$3.82M
5
SWTX
SpringWorks Therapeutics
SWTX
+$3.76M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$3.84M
3
TVTX icon
Travere Therapeutics
TVTX
+$3.64M
4
ONC
BeOne Medicines Ltd
ONC
+$3.22M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.09T
$9.26M 6.26%
10,447
+747
+8% +$672K
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$6.55M 4.43%
43,849
+23,849
+119% +$3.22M
BBIO icon
3
BridgeBio Pharma
BBIO
$16.8B
$5.37M 3.63%
211,000
+132,093
+167% +$3.47M
GPCR icon
4
Structure Therapeutics
GPCR
$3.4B
$5.27M 3.57%
+120,165
New +$4.65M
TGTX icon
5
TG Therapeutics
TGTX
$8.4B
$4.86M 3.28%
207,627
-43,973
-17% -$960K
ALGN icon
6
Align Technology
ALGN
$12.6B
$4.76M 3.21%
+18,700
New +$4.41M
CI icon
7
Cigna
CI
$79.6B
$4.23M 2.86%
12,200
– –
GILD icon
8
Gilead Sciences
GILD
$167B
$4.19M 2.83%
+50,000
New +$3.82M
GERN icon
9
Geron
GERN
$930M
$4.11M 2.78%
+905,126
New +$4.12M
BNTX icon
10
BioNTech
BNTX
$23.4B
$4.1M 2.77%
+34,552
New +$3.18M
BMY icon
11
Bristol-Myers Squibb
BMY
$130B
$4.04M 2.73%
+78,000
New +$3.66M
VRDN icon
12
Viridian Therapeutics
VRDN
$2.15B
$3.97M 2.68%
+174,400
New +$2.85M
ISRG icon
13
Intuitive Surgical
ISRG
$130B
$3.65M 2.47%
7,427
+1,069
+17% +$498K
ONC
14
BeOne Medicines Ltd
ONC
$34.3B
$3.44M 2.32%
15,300
-17,900
-54% -$3.22M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$3.39M 2.29%
+36,700
New +$3.65M
GKOS icon
16
Glaukos
GKOS
$8.89B
$3.37M 2.28%
+25,857
New +$3.22M
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
$3.23M 2.18%
+100,700
New +$3.76M
IRON icon
18
Disc Medicine
IRON
$2.85B
$3.17M 2.14%
64,516
+3,516
+6% +$165K
CYTK icon
19
Cytokinetics
CYTK
$10.8B
$3.09M 2.09%
+58,583
New +$3.27M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$2.14B
$2.94M 1.99%
+66,200
New +$3.01M
RLAY icon
21
Relay Therapeutics
RLAY
$3.99B
$2.94M 1.98%
+414,629
New +$3.1M
APLS
22
DELISTED
Apellis Pharmaceuticals
APLS
$2.89M 1.96%
100,367
+53,467
+114% +$1.98M
RDY icon
23
Dr. Reddy's Laboratories
RDY
$9.77B
$2.88M 1.95%
181,500
– –
NTRA icon
24
Natera
NTRA
$36.1B
$2.85M 1.93%
22,450
+3,800
+20% +$436K
BIIB icon
25
Biogen
BIIB
$30.4B
$2.57M 1.74%
+13,317
New +$2.79M
1
2 3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
GIO
Galilei Investment Office London, United Kingdom $193M AUM 16.19% 1-Year Est. Return

Exome Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Exome Asset Management held 82 positions worth $148M, up 32% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Exome Asset Management deployed $28.1M of net new capital in Q3 2024, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was Structure Therapeutics: 120,165 shares worth $5.27M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $3.22M trimmed.

  • Exome Asset Management's largest Q3 2024 buy was Structure Therapeutics: 120,165 shares worth $5.27M.
  • Exome Asset Management added most to BridgeBio Pharma in Q3 2024, an estimated $3.47M increase.
  • Exome Asset Management's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $3.22M.
  • Exome Asset Management fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $5.2M.
  • Exome Asset Management's ten largest holdings make up 36% of its $148M portfolio in Q3 2024.
  • Exome Asset Management opened 30 new positions and closed 23 in Q3 2024.
  • Exome Asset Management's portfolio value rose 32% quarter-over-quarter to $148M.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.